Gilead Sciences, Inc (NASDAQ:GILD) Receives Consensus Recommendation of Hold from Analysts theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Gilead Sciences (NASDAQ:GILD – Free Report) had its target price reduced by Barclays from $80.00 to $76.00 in a report issued on Monday, Benzinga reports. They currently have an equal weight rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently weighed in on the stock. Truist Financial cut shares of Gilead […]
Gilead Sciences (NASDAQ:GILD – Free Report) had its price target trimmed by Maxim Group from $90.00 to $85.00 in a research report sent to investors on Wednesday, Marketbeat Ratings reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. Several other equities analysts also recently weighed in on the company. Truist Financial […]
Gilead Sciences (NASDAQ:GILD – Free Report) had its price objective lowered by Barclays from $80.00 to $76.00 in a report released on Monday morning, Benzinga reports. Barclays currently has an equal weight rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently issued reports on GILD. HSBC raised shares of Gilead Sciences […]
Gilead Sciences (NASDAQ:GILD – Free Report) had its price objective lowered by Barclays from $80.00 to $76.00 in a research report released on Monday morning, Benzinga reports. Barclays currently has an equal weight rating on the biopharmaceutical company’s stock. A number of other equities research analysts have also recently commented on GILD. Truist Financial cut […]